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We outline an ambitious project to characterize the genetic and epigenetic regulation of multiple facets of
transcription in distinct brain regions across the human lifespan in samples of major neuropsychiatric disor-
ders and controls. Initially focused on schizophrenia and mood disorders, the goal of this consortium is to
elucidate the underlying molecular mechanisms of genetic associations with the goal of identifying novel
therapeutic targets. The consortium currently consists of seven pharmaceutical companies and a not-for-
profit medical research institution working as a precompetitive team to generate and analyze publicly avail-
able archival brain genomic data related to neuropsychiatric illness.Motivation for the Consortium
It has become a virtual cliche´ to opine that
there is an unmet medical need for the
development of novel medicines for psy-
chiatric disorders, as novel treatment
approaches have stalled for decades (Hy-
man, 2012). Schizophrenia in particular is
facing a crisis. There has been a complete
lack of success in delivering drugs against
novel therapeutic targets that show
consistent efficacy in clinical trials, there
has been onlymarginal success in treating
the negative and cognitive domains that
are not treated by current therapies, and
there are lingering adverse effect profiles
with these same compounds (Coyle,
2006). Developing the next generation of
central nervous system (CNS) therapies
for psychiatric disorders requires adeeper
understanding of the underlyingmolecular
mechanisms contributing to illness based
on human data.
It is generally believed that the applica-
tion of human genetic findings to drug dis-
covery may provide a rational entry point
to better understand disease mecha-
nisms at the phenotypic, molecular/
cellular, and neurocircuitry levels. Recent
successes in psychiatric genetics include
the publication of 108 significantly associ-
ated common loci for schizophrenia by
the Psychiatric Genomics Consortium
(PGC) identified by genome-wide associ-
ation analysis (GWAS) (Schizophrenia
Working Group of the Psychiatric Geno-
mics Consortium, 2014) and the identifi-
cation of multiple rare de novo mutations
associated with autism spectrum disor-
ders (De Rubeis et al., 2014; Iossifov1078 Neuron 88, December 16, 2015 ª2015et al., 2014). Such advances instill opti-
mism that new therapeutic hypotheses
can be derived, and ultimately tested in
the clinic, based on models that will be
informed by an understanding of the mo-
lecular mechanism underlying the genetic
association (Schubert et al., 2014). How-
ever, GWAS is a variant-based associa-
tion method: it identifies often broad
genomic loci containing multiple, some-
times hundreds, of correlated disease-
associated variants and usually does not
identify the disease-associated gene(s).
More importantly, the association alone
says little about the biological function or
role of the locus in disease. GWAS results
therefore lead to four important ques-
tions: (1) which variant(s) within the identi-
fied locus are responsible for the disease
association, (2) which gene(s) do they
act through, (3) is there a specific patho-
genic transcript, and (4) do the functional
consequences relate to disease-associ-
ated altered expression?
The first step in translating these
exciting genetic findings into transforma-
tive medicines is the mapping of SNP-to-
gene-to-function, which is critical to link
the information from genetic association
to disease biology through the functional
impact of implicated genetic variations.
The availability of large transcriptional da-
tasets from relevant case and control tis-
sues is a critical component for such an
analysis. As well as enhancing our general
understanding of disease biology, this will
aid in drug development by providing a
clue to a pathogenic gene product and
insight to molecular directionality of theElsevier Inc.associated product, thus initiating model
building based on amolecularmechanism
of risk to close in on potential new targets.
Here, we discuss a new precompetitive
initiative launched by the Lieber Institute
for Brain Development (LIBD) with phar-
maceutical industry partners (Astellas
Pharma, AstraZeneca, Eli Lilly and Com-
pany, F. Hoffmann-La Roche, Johnson
and Johnson, Lundbeck and Pfizer) to
take advantage of the emerging and previ-
ously unprecedented genetic knowledge
of psychiatric disorders and technical
advances in the analysis of gene expres-
sion in brain tissue: BrainSeq, A Human
Brain Genomics Consortium. Utilizing the
growing brain tissue repository at the
LIBD, with over 1,900 human postmortem
neuropsychiatric disease and control
samples available, the primary goal of
BrainSeq is to generate and analyze
spatial and temporal neurogenomics
data (e.g., genotype, RNA sequence, and
DNAmethylation) and to establish a public
database of these results. Short-term
goals of the consortium are to determine
how neurogenomics data can be used to
elucidate the underlying molecular mech-
anisms of the genetic associations being
discovered for psychiatric disorders, as
well as the development of new bioinfor-
matics tools and industry standards for
scientific discovery in neurogenomics.
The long-term goal is to develop new pre-
clinical hypotheses that can drive the
nomination of novel treatment targets.
While initially focused on schizophrenia
and mood disorders and recently identi-
fied common risk loci (Schizophrenia
Figure 1. Mechanisms of Biological Risk from Noncoding Genetic Variation
Noncoding variation affects gene function via diverse mechanisms, but all are read out in the tran-
scriptome. * Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014.
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mics Consortium, 2014), the structure of
BrainSeq and the ongoing analyses have
broad applications and implications for
other complex genetic disorders. The
LIBDbrain repository additionally includes
brains of individualswith anxiety disorders
diagnoses and with neurodegenerative
disorders and is the largest collection of
brains of individuals with post-traumatic
stress disorder (PTSD). BrainSeq will
involve the analysis of multiple brain re-
gions on largely the same individuals
across the human lifespan, from fetal life
to old age, in a large sample of control
brains and in samples from various psy-
chiatric and neurological disorders. The
brain specimens of neuropsychiatrically
affected individuals available as part of
this project are particularly informative in
that they are relatively young (mean age
46 years) and have been ill for relatively
short periods of time, thus reducing
the impact of chronic illness-associated
epiphenomena (see Table S2)
The genetic architecture of complex
disorders involves primarily sequence
variation that influences gene regulation
(e.g., transcript abundance, splicing,
novel transcript architecture, translation
efficiency) rather than protein sequence
(Fu et al., 2013). Thus, the molecular iden-
tification of genetic regulation of the tran-
scriptome is a critical step in understand-
ing genetic mechanisms and discoveringnovel isoforms that may underlie disease
mechanisms and that may be targetable
for the development of new therapies. In
other words, regardless of the specific
molecular mechanism of the genetic vari-
ation (e.g., promoter regulation, splicing,
microRNA, long non-coding RNA, epige-
netic processes), we argue that if the
variant is not a protein coding variation,
the primary readout should ultimately
manifest as an effect in the transcriptome
(see Figure 1). Even for regulatory variants
affecting translation, it is possible to
elucidate their impact by measuring the
transcriptome from purified translating
polyribosomes (Sterne-Weiler et al.,
2013), a project that can be initiated in
future stages of BrainSeq.
As illustrated in Figure 2, the principle of
gene-to-drug approaches is based on
identifying a molecular mechanism in the
transcriptome that accounts for the clin-
ical association and then building cell
and animal models based on the molecu-
lar species identified. This represents an
approach to model building with a high
level of construct validity, modeling the
specific molecular pathology of illness
and genetic risk, in contrast to traditional
models based on overall gene up- or
downregulation. The ideal convergence
of molecular association would be the
identification of a specific transcript asso-
ciated both with the illness state and with
genetic risk, and with the risk-associatedNeuron 88, Degenotype predicting the same direction-
ality of expression difference between
cases and controls. In such a case,
knowing the directionality of themolecular
mechanism underlying the clinical associ-
ation will suggest how to target it phar-
macologically (i.e., with antagonists or
agonists). Recent data suggest that risk-
associated loci for psychiatric disorders
based on common variation influence
expression of specific, often previously
unannotated splice variants (Tao et al.,
2014), illustrating the importance of in-
depth RNA characterization to identify
potentially pathogenic transcripts, which
may be of relatively low abundance. The
risk-associated transcript and its expres-
sion differential is the specific construct
for building preclinical models.
Full-length transcript assembly is a
challenge with current short read
sequence technologies (Bradnam et al.,
2013; Steijger et al., 2013). The BrainSeq
RNA-seq protocol involves paired-end
RNA sequencing of 100 base pair (bp)
fragments. Though the BrainSeq depth
of sequencing is considerable (approxi-
mately 100 million reads/sample), which
allows identification of relatively rare tran-
scripts, assembly is not straightforward.
As outlined below, the BrainSeq analytic
team will quantify reads that are assigned
to genes, exons, and splice junctions. The
latter may prove especially informative in
identifying previously unannotated tran-
script fragments for more detailed investi-
gation, including followup with targeted
long-read technology.
Description of the LIBD Brain
Cohort
Tissue Accrual
The LIBD Postmortem Human Brain
Collection (HBC) has acquired informed
consent from relatives of the deceased
for 751 postmortem human brain samples
(average of 21 brains per month) through
the Office of the Chief Medical Examiner
of the State of Maryland from September
2012 through early December 2015. Addi-
tionally, the collection has 1,213 postmor-
tem human brain tissue samples acquired
via material transfer agreements, includ-
ing those from the National Institute of
Mental Health (NIMH), the Eunice Ken-
nedy Shriver National Institute of Child
Health and Development (NICHD) Brain
Bank, the Stanley Medical Researchcember 16, 2015 ª2015 Elsevier Inc. 1079
Figure 2. Roadmap of Genes to Drug Discovery
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NeuroViewInstitute, and The Johns Hop-
kins University. The BrainSeq
consortium has committed
initial resources for comple-
tion of four phases of RNA-
seq processing and analysis,
based on specific brain re-
gions and clinical diagnoses.
The BrainSeq Phase I tissue
cohort consists of a diag-
nostic mix of 746 postmortem
human brain samples from
the dorsolateral prefrontal
cortex. Phase II samples
consist of 200 patients with
schizophrenia and 300 con-
trols from mid hippocampus.
Phase III involves head ofcaudate tissue from a similar sample of
patients with schizophrenia and controls.
Phase IV consists of hippocampal and
medial prefrontal cortex tissues from con-
trols and patients with bipolar disorder
and major depression, who are psycho-
tropic drug-free at time of death. All brain
donations are obtained by verbal, wit-
nessed informed consent with the next-
of-kin (see Table S1).
Consenting and Clinical Review
Process
The LIBD conducts retrospective clinical
diagnostic reviews on every donation,
which consist of: (1) a 34-item telephone
screening with the next-of-kin on the
day of donation conducted by a board-
certified psychiatrist or board-certified
neurologist to gather demographic, med-
ical, medication, social, psychiatric
symptoms, treatment, and other clinical
history; (2) a macroscopic and micro-
scopic neuropathological examination by
a board-certified neuropathologist to
screen for neuritic pathology and to
exclude cases with evidence of cerebro-
vascular accidents, tumors, contusions,
and neurodegenerative disorders; (3) au-
topsy information (cause, manner of
death, contributing conditions to death,
circumstances surrounding death) and
any related history gathered through the
medical examiner; and (4) a comprehen-
sive toxicological analysis to screen for
illicit and basic drugs and acute drug
intoxication. Further, every case has a
forensic postmortem toxicological anal-
ysis, to include volatiles (ethanol), and a
comprehensive drug screening (illicit
drugs including cocaine and metabolites,1080 Neuron 88, December 16, 2015 ª2015opiates and metabolites, phencyclidine
[PCP], amphetamines, antihistamines,
and other prescription drugs including an-
tidepressants, antipsychotics, and mood
stabilizing agents). If any testing is incom-
plete through the medical examiner, sup-
plemental toxicology testing is ordered
through National Medical Services, Inc.
to screen for additional drugs on a case-
by-case basis, aswell as for cannabinoids
and nicotine and cotinine levels.
Additionally, for every psychiatric case,
extensive medical records review, con-
tact with treating physicians, and/or
family informant interviews (LIBD psycho-
logical autopsy interview, the Structured
Clinical Interview for DSM-IV Disorders
[SCID], or Mini International Neuropsychi-
atric Interview [MINI]) are conducted,
where applicable and available. A mas-
ter’s-level clinician summarizes all of
these data into a neuropsychiatric narra-
tive summary, which is then reviewed
and scored by two board-certified psychi-
atrists, to determine lifetime psychiatric
diagnoses according to DSM-IV/V.
Tissue Quality Measures
Every case has a postmortem interval (in
hours) calculated as the difference be-
tween the time the brain was frozen from
the time the patient was pronounced or
estimated to have last been alive if the
death was unattended. Every brain has a
pH measure (in cerebellar tissue) for
determining basic tissue quality. RNA
Integrity Number (RIN) is measured on
specific brain regions as they are
dissected and processed for specific
research studies (e.g., dorsolateral pre-
frontal cortex [DLPFC] RIN, hippocampalElsevier Inc.RIN, caudate RIN, medial
prefrontal cortex RIN, etc.),
prior to the RNA-seq data
described below.
Sample Selection and
Processing
All samples selected for mo-
lecular genetic analyses are
dissected from deep-frozen
tissue in a standardized
routine by the same individ-
ual, using a dental drill tomini-
mize tissue injury and RNA
degradation. The initial four
phases of the BrainSeq work
are focused on dorsolateral
prefrontal cortex (Brodmann
area [BA] 9, 46), mid-hippo-campus, caudate nucleus head, and
medial prefrontal cortex (BA 32), because
these are brain regions consistently and
repeatedly identified as functionally
altered in patients with schizophrenia
and mood disorders, and the functional
connection between these regions also
shows alterations in patients (Cocchi
et al., 2014; Rasetti et al., 2014; Rasetti
and Weinberger, 2011; Tan et al., 2006).
Moreover, recent work using in vivo func-
tional imaging approaches has identified
physiological alterations in these brain re-
gions as being associated with increased
genetic risk for these disorders in the
healthy unaffected siblings of patients
(Callicott et al., 2003; Rasetti et al., 2011;
Sambataro et al., 2013)
Human Brain Neurogenomic Data in
BrainSeq
The large-scale datasets generated by
BrainSeq provide an unprecedented op-
portunity to interrogate the functional
consequences of genetic risk variants on
the transcriptome and the epigenome in
the same subject samples (see Table S1).
Genotype/Genetic Data
Imputation from observed microarray-
based genotyping yields more complete
genetic information on every sample.
Briefly, all subjects were genotyped using
cerebellar DNA with an Illumina geno-
typing microarray platform—the majority
of genotyping utilized the Illumina
Human1M-Duo BeadChip with subsets
of samples genotyped using the Illumina
HumanHap650Yv3 BeadChip, Omni2.5
BeadChip, orOmni5BeadChip.Pre-impu-
tation quality control steps, performed
Neuron
NeuroViewseparately for each chip type, largely
mirror recommended guidelines for pre-
GWAS data processing (Anderson et al.,
2010) and involve removing low-quality
and/or rare variants. Cleaned observed
data on each genotyping platform are
phased into haplotypes using SHAPEIT
(Delaneau et al., 2013) and imputed to
the 1000 Genomes Phase 3 variant set
reference panel for the autosomal chro-
mosomes and Phase 1 variant set for
chromosome X, using Impute2 (Marchini
et al., 2007). Post-imputed genetic data
are then merged across genotyping plat-
forms, resulting in over 80 million genetic
variants, consisting of single nucleotide
variants (SNVs), insertions and deletions
(indels), duplications and repeat elements,
per individual. There are approximately
7.5 million common and high-quality
variants (minor allele frequency, MAF,
>5%; Hardy-Weinberg Equilibrium, HWE,
p value > 106; and non-missing genotype
data across >90% of the subjects), which
can be correlated with transcriptome and
epigenome data to identify the regulatory
role of risk-associated genetic variation
in the human brain.
RNA Sequencing/Transcriptome
Data
Following RNA extraction from relevant
brain regions, RNA sequencing libraries
are constructed following the manufac-
turer’s protocols using two different Illu-
mina kits: polyA+ selection for DLPFC
samples (see additional details in Jaffe
et al., 2015) and RiboZero Standard
depletion for DLPFC, hippocampus,
caudate nucleus, and medial prefrontal
cortex samples. These RiboZero se-
quencing libraries are also prepared with
ERCC spike-ins for data normalization
(Risso et al., 2014) and also employ a
strand-specific protocol. Sequencing li-
braries are barcoded to allow for multiple
samples to be run across different flow
cells and lanes to reduce potential biases
induced by individual lanes, and samples
resequenced using the Illumina HiSeq
2000 and HiSeq 3000 paired-end 100-bp
reads targeting approximately 100 million
reads per sample. The resulting se-
quencing reads are assessed using the
FastQC tool, and the metrics are
retained for each sample for downstream
analysis. These sequencing reads are
aligned to the genome using a splice-
aware aligners TopHat2 (Kim et al.,2013), STAR (Dobin et al., 2013), or
GSNAP (Wu and Nacu, 2010), and
expression levels for different features
can be summarized for each sample, for
example across annotated genes and
exons (Liao et al., 2014), splice junctions,
expressed sequences (Jaffe et al., 2015),
and transcripts (Frazee et al., 2015; Trap-
nell et al., 2013).
DNA Methylation/Epigenetic Data
Following DNA extraction from relevant
brain regions, Illumina HumanMethyla-
tion450 BeadChip microarrays (Sandoval
et al., 2011) are run on each sample
following bisulfite conversion using the
manufacturer’s protocols. Resulting im-
age files (.idat) are processed and quality
controlled using the minfi Bioconductor
package (Aryee et al., 2014), resulting in
proportion DNA methylation levels for
>485,000 CpG sites across the epige-
nome on each sample.
Leveraging Neurogenomics Data to
Advance Treatment of
Schizophrenia
Schizophrenia and bipolar disorder are
common, debilitating, neuropsychiatric
disorders with enormous public health
costs. Although efficacious, current treat-
ments are far from ideal, as many patients
fail to respond, as about one third of pa-
tients with schizophrenia are treatment-
resistant (Smith et al., 2009). Of those
who do respond, many only improve
partially, leaving residual negative symp-
toms and cognitive deficits. In addition,
adverse drug reaction and side effects
remain major issues with both typical
and atypical antipsychotics (Leucht
et al., 2013), leading to treatment failure
because of lack of tolerability and poor
compliance. Antipsychotics, especially
atypicals such as clozapine, are multi-
target drugs, i.e., they bind to multiple
neurotransmitter receptors and other
molecules. However, of all the molecular
targets of antipsychotics, the occupancy
of the dopamine D2 receptor remains a
necessary condition for antipsychotic ac-
tivity of all currently marketed drugs,
despite attempts to develop alternative
treatments (Ginovart and Kapur, 2012).
The success of the PGC (Schizophrenia
Working Group of the Psychiatric Geno-
mics Consortium, 2014) in identifying
108 loci associated with schizophrenia
provides the opportunity to refine, andNeuron 88, Demove away from, prior simple neurotrans-
mitter hypotheses of schizophrenia. Inter-
estingly, the dopamine D2 receptor maps
to one of the 108 loci, possibly supporting
the promise of the GWAS approach in
identifying drug targets. Of themany other
genes within loci identified by the PGC,
many are highly attractive and tractable
drug targets, some of which have previ-
ously been the target of drug develop-
ment programs. These include GRIN2A,
which encodes the NMDA (N-methyl-d-
aspartate) receptor subunit NR2A, a key
mediator of synaptic plasticity (Yashiro
and Philpot, 2008), and GRIA1, which
encodes glutamate receptor 1 (GluR1;
also known as GluA1), an AMPA
(a-amino-3-hydroxy-5-methyl-4-isoxazo-
lepropionic acid) receptor subunit that
mediates fast synaptic transmission and
is important for learning and memory
(Sanderson et al., 2008). The PGC regions
also contain SRR, which encodes serine
racemase, an enzyme that catalyzes the
conversion of L-serine to D-serine and is
an essential co-agonist and activator of
NMDA receptors (Campanini et al.,
2013); CACNA1C, which encodes the
alpha 1C subunit (Cav1.2) of the L-type
voltage-gated calcium channel (Bhat
et al., 2012); and CACNA1I, which en-
codes the pore-forming alpha subunit of
the Cav3.3 T-type calcium channel
involved in synaptic plasticity and long-
term potentiation. GRM3 encodesmetab-
otropic glutamate receptor 3 (mGluR3)
predominantly expressed in astrocytes
and is also implicated by the PGC
GWAS results. Drugs with activity against
mGluR2 and mGluR3 have been exten-
sively explored as a potential therapeutic
target in schizophrenia, but clinical
studies to date have shown mixed results
with regard to efficacy compared to cur-
rent standard of care, and Phase III trials
have not been successful so far (Li et al.,
2015). It is conceivable that the failure to
show efficacy in large Phase III studies is
becausemGluR3 has not been selectively
targeted. Other reasons for this failure
have been debated elsewhere (Dunlop
and Brandon 2015). Characterization of
the molecular association in human brain
may clarify how the genetic association
influences the gene product, specifically
whether there is a novel GRM3 isoform
in brain andwhether it is up- or downregu-
lated in illness.cember 16, 2015 ª2015 Elsevier Inc. 1081
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from psychiatric disorders into drug
development is the definition of the pre-
cise molecular isoforms of these genes
and their products that contribute to
disease and their dysfunctional role in
physiological pathways. By first defining
the pathways and networks perturbed
according to transcriptome analyses, it
becomes possible to prioritize the most
critical components of these pathways
to target through in silico systems phar-
macology or other bioinformatics ap-
proaches. We are optimistic that the pos-
sibility of identifying disease-associated
gene isoforms, pathways, networks, and
pathophysiological mechanisms through
genomic research will catalyze drug dis-
covery and development with novel
mechanisms of action based on causa-
tion, not phenomenology. In so doing,
this will also allow us to revisit previously
unsuccessful targets armed with new
knowledge about their biological role in
disease and about patient subpopula-
tions in which a therapeutic aimed at
these targets may be efficacious. Indeed,
by focusing on gene variants with func-
tional impact at molecular levels, their ef-
fect on clinical intermediate phenotypes
could be investigated in living patients,
suggesting subgroups that may benefit
more from target modulation.
BrainSeq Expected Outcomes to
Identify Novel Treatments
We expect that the BrainSeq data anal-
ysis and integration approach will pro-
vide us with sufficient genetic substrate
to generate novel and testable biological
and therapeutic hypotheses for schizo-
phrenia, mood disorders, and related
neuropsychiatric conditions. Based on
an improved understanding of the tran-
scriptomic and epigenomic effects of ge-
netic disease-associated risk variants in
relevant brain regions, we expect to be
able to identify a significant subset of
the truly causal genes and isoforms
implicated by GWAS signals. Such
causal gene mapping, combined with
the ability to assign a directionality hy-
pothesis to a disease locus as well as
prior literature evidence, will significantly
improve our chances to accurately
assess the underlying disease biology
and identify a path toward novel and bet-
ter therapeutics.1082 Neuron 88, December 16, 2015 ª2015Data- and Biospecimen-Sharing
Plans
In addition to an active precompetitive
research project, a fundamental principle
of this consortium is to provide the scien-
tific community at large with a valuable
resource for future research. Data will be
made available to approved investigators
through a web-based portal hosted at
LIBD through the BrainCloud application
(in raw and/or processed forms) to allow
for additional analyses and comparison
with other datasets outside this con-
sortium. The consortium will endeavor to
publish data and consortium research re-
sults promptly to make them publically
available. As a rule, all data will be
released within one year of completion
of the consortium data analysis. Data
from the control and schizophrenia cohort
of the Phase I of the consortiumwork plan
is expected to be released by early 2016.
The Phase II data results will be released
in 2016. Phase III and IV data will be
available in 2017. At any time, the con-
sortium is open to accepting new mem-
bers to expand the scope of the work
plan and to allow early access to the
research results and participation in
ongoing analyses.
As the ability to perform additional
studies on brain and tissue samples con-
tained in the consortium data is antici-
pated, a procedure will be put in place
to propose such studies. This may include
molecular analysis of specific cell popula-
tions using laser capture and cell-sorting
techniques, targeted resequencing with
longer read technologies, whole-genome
bisulfite sequencing, and chromatin state
assays, as well as peptide sequencing.
Future Plans
We envision that BrainSeq will produce
valuable information in its first planned
phases about the molecular pathways
associated with schizophrenia, mood
disorders, and related conditions in the
DLPFC, medial prefrontal cortex, hippo-
campus, and caudate, which shall
facilitate the development of novel
mechanistic and therapeutic hypotheses
for the discovery and development of
novel treatment targets. As the cost of
next-generation sequencing technologies
continues to decrease, the consortium
anticipates the potential addition of
whole-genome sequencing approachesElsevier Inc.to the data generation pipeline, as well
as analysis of small RNA species to the
analytic pipeline.
In closing, the BrainSeq precompetitive
multi-partner consortium, applying a
multi-omics approach with a highly
collaborative spirit, combined with clear
data-sharing policies and pre-defined
analysis plans, allows for ready scalability
and the potential to significantly accel-
erate psychiatric drug discovery. This
approach is especially warranted for
neuropsychiatric disorders, where the
clinical and genetic heterogeneous nature
of the disease poses special problems for
drug discovery. Yet we hope that our ef-
forts will ultimately have broader applica-
bility to other complex disorders, where
the understanding of genotype-pheno-
type relationships is critical to elucidate
the underlying molecular nature of dis-
ease etiology.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two tables and
can be foundwith this article online at http://dx.doi.
org/10.1016/j.neuron.2015.10.047.
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